News concerning Defymed: research, innovation, business

News

Home News

Defymed at the annual conference of the European Society for Biomaterials (ESB)

August 09 2022

4-8 September: Defymed at the annual conference of the European Society for Biomaterials (ESB) Elisa...

02 June 2022: Séverine Sigrist joins the French team of Women Leaders

June 03 2022

02 June 2022: Séverine Sigrist joins the French team of Women Leaders On May 10th, we invited you to...

13 – 16 June: Defymed at the BIO International Convention in San Diego

May 25 2022

13 – 16 June: Defymed at the BIO International Convention in San Diego Richard...

12-13 May: Defymed at the Meet2Win convention

May 05 2022

12-13 May: Defymed at the Meet2Win convention Our president Séverine SIGRIST will be present at the...

Defymed and GlioCure initiate collaboration in the field of solid tumours without therapeutic options

April 20 2022

Press release Strasbourg and Angers, 20th April 2022 Defymed and GlioC...

Defymed at the International Conference on Advanced Technologies and Treatments of Diabetes (ATTD)

April 14 2022

April 27th – 30th : Defymed at the International Conference on Advanced Technologies and Treatments...

DEFYMED at SFD congress in Nice (France)

February 04 2022

March 22-25th: Defymed at the French Society of Diabetes (SFD) congress Several people of the team (...

Defymed will start its pilot clinical study with ExOlin®

January 26 2022

The French authorities validate the start of the therapeutic trial to evaluate the safety of the Ex...

Defymed at the IPITA conference

October 20 2021

October 20th-22nd : Defymed at the International Pancreas and Islet Transplantation Association (IPI...

Defymed at the Cell and Gene meeting on the MESA 2021

September 14 2021

October 12th-14th & 19th-20th : Defymed at the Cell and Gene meeting on the MESA 2021 Defymed wi...

Defymed at the conference of the European Society for Biomaterials

July 27 2021

September 5th-9th: Defymed at the conference of the European Society for Biomaterials Last year Defy...

Defymed at ISCT 2021 virtual congress

April 29 2021

May 26th – May 28th: Defymed is happy to announce its participation to annual congress of ISCT...

Defymed at the SNITEM day

March 16 2021

April 13th, 2021 – In a month Defymed will participate to the 6th days of SNITEM. After a canc...

Defymed participates in the SFD virtual congress 2021

February 19 2021

March 23-26th 2021 : Defymed is happy to announce its participation in the SFD (French diabetes soci...

Defymed at EAHAD congress 2021

January 20 2021

February 3-5th 2021 : Defymed is very happy to announce its participation in the EAHAD (European Ass...

A new notified body for ISO13485:2016 certification of Defymed

January 12 2021

Defymed ISO 13485 :2016 Communication TuvSud Defymed is proud to announce the certification transfer...

Defymed at Biotech Showcase and Bio partnering at JP Morgan

December 16 2020

January 11-15th 2021: Defymed is happy to participate to the Biotech showcase and Bio Partenring at...

Defymed at World Biomaterials Virtual Congress 2020

December 09 2020

Defymed at World biomaterials congress December 11-15th 2020: After a complicated year to mai...

Defymed at the JDRF Fall Beta Cell Replacement Consortium

November 17 2020

Novembre 17-18th, 2020 : Defymed is looking forward to participate to the «Fall Beta Cell Replacemen...

Defymed at ESMO Virtual Congress 2020

August 21 2020

September 19-21th 2020 : Defymed is happy to announce that we will assist to the ESMO Virtual Congre...

The interview of Séverine Sigrist about Defymed and the ExOlin® medical device

June 22 2020

Discover the interview of Séverine Sigrist, the Chief Executive and Scientific Officer of Def...

A video to better understand the medical device ExOlin

June 16 2020

A video to better understand the medical device ExOlin®! To understand how the ExOlin® device...

Safety and function of MailPan bioartifical pancreas, Defymed’s second scientific paper

May 28 2020

“Safety and function of a new pre-vascularized bioartificial pancreas in an allogeneic rat mod...

Defymed: a new fund raising round to allow the entry into clinical phase of its ExOlin® device

May 05 2020

Towards a physiological treatment for Type 1 diabetes A new fund raising round for Defymed, to allow...

Defymed at #SFD2020 in Brussels, Belgium

March 02 2020

September 8-11th 2020 : Defymed is happy to announce that we will be present at the annual Internati...

Defymed is now on Facebook

February 26 2020

Please follow our new page and do not hesitate to share with your contacts in your social media: ==&...

First scientific paper of Defymed about @ExOlin an ExtraPeritoneal delivery of insulin in an international journal “Journal of Controlled release”

February 11 2020

February 11th, 2020: We are pleased to announce the publication of our article “A fully implan...

Defymed at #ATTD2020 in Madrid-Spain

January 29 2020

Madrid, February 19-22th 2020: Defymed is happy to announce that we won the “Startup Grant for the T...

Defymed at 25th annual international partnering BIO-Europe in Hambourg

October 16 2019

November, 11-13th 2019: Defymed is happy to announce that we will be present at the 25th annual BIO-...

Defymed at IXA2019 in Munich

October 08 2019

Munich, October 10-13th 2019: Defymed’s CEO, Séverine Sigrist and COO, Richard Bouaoun are glad to p...

Defymed accelerates its development in the United States: one step closer to patients

September 24 2019

From September 25th till October 05th, Defymed will be exploring, thanks to the Innouvo program, new...

Defymed at INTERNATIONAL PANCREAS & ISLET TRANSPLANT ASSOCIATION in Lyon-FRANCE

July 04 2019

Lyon, July 2-5th 2019: Defymed will participate to the 17th World Congress of the IPITA (INTERNATION...

Defymed in booth A6 at MedFIT in Lille-France

May 23 2019

Lille, June 25-26th 2019: As Defymed won the “Start-up Slams” contest in MEDFIT Strasbourg last year...

Defymed at the « 2019 Innovative start-up day of the medical device »

April 26 2019

Paris, May 14th 2019: We are very happy to participate to this 2019 innovative start-up day organize...

Defymed receives support from Grand-Est region and French ministry of Economy

April 23 2019

The MedTech company Defymed from Strasbourg has obtained a grant of 230,000 euros for the developmen...

Defymed at SFD (Francophone Diabetology society) in Marseille – FRANCE

March 18 2019

Marseille, March 26-29th 2019: Defymed will participate to the annual congress of the Francophone Di...

Defymed at ATTD2019 in Berlin-Germany

January 28 2019

Berlin, February 20-23th 2019: Defymed will participate to the 12th International ATTD 2019 (Advance...

Defymed – Winner of the first Innovation Prize

December 07 2018

The trophy of the Grand Est Trophies 2018 for the Innovation Award and the devices MailPan and ExOli...

Defymed at EASD2018 in Berlin

August 29 2018

Berlin, October 1-5th 2018: Defymed is very proud to announce that we have been selected to present...

Defymed wins MedFIT 2018 Start-up slams

July 16 2018

Audience prize-DEFYMED-MedFIT2018 Strasbourg, June 26-27th 2018: MedFIT 2018, a European business co...

Defymed at MedFIT in Strasbourg-France

June 15 2018

Strasbourg, June 26-27th 2018: We are happy to announce that Defymed won the “Start-up Slams” and i...

Defymed at “Innovative start-up day of the medical device”

May 31 2018

Paris, June 6th 2018: We are very happy to participate for the second time to this innovative start-...

Defymed Collaborates with Israeli SME Kadimastem to Validate a Combined Solution for Type 1 Diabetic Patients (in French)

April 25 2018

Strasbourg, FRANCE, April 2018 : Medical device developer Defymed announced today the signing of a m...

Defymed strengthens its position as a worldwide leader

February 13 2018

Strasbourg, France, February 2018: French-based Medtech company Defymed confirms its global position. Recognized by its peers for the development of two innovative medical devices – ExOlin®, an insulin delivery device, and MailPan®, a bioartificial pancreas – the company intends to strengthen its position as a worldwide leader in innovative physiologic...

Defymed at ATTD (Booth #33) in Vienna – Austria

February 05 2018

Vienna, February 14-17th 2018: We are happy to announce that Defymed won the “Startup Grant for the...

Upgrade of Defymed’s certification to meet the ISO13485:2016 requirements

January 10 2018

Strasbourg, January 10th 2018: Defymed is proud to announce that its quality management system was a...

Defymed at BIO-Europe in Berlin – Germany

September 28 2017

Berlin, November 6-8th 2017: Defymed is happy to announce that we will be present at the 23rd annual...

Defymed at the 53rd annual meeting of the EASD in Lisbon – Portugal

July 21 2017

Lisbon, September 11-15th 2017: Defymed will particpate at the 53rd annual meeting of the European A...

ExOlin ®, a new insulin delivery device under development by Defymed

July 10 2017

Strasbourg, 10th July 2017: Targeted at persons suffering from diabetes (Type 1 diabetics and some...

FP7 European collaborative project BIOSID reaches its end

June 12 2017

Strasbourg, 12th June 2017 : BIOSID is an European project coordinated by the European Diabetes Stud...

Defymed at the JDRF Encapsulation Consortium – New York

May 04 2017

11-12 May 2017: Defymed will be present at the JDRF Encapsulation Consortium that will be held in New York – USA. Defymed will present the latest results on MailPan ®’s Bioartificial Pancreas development. This privileged group gathers worldwide key opinion leaders in the field of Cell therapy and Encapsulation for the treatment of Type1 Diabetes. For more in...

Defymed will be present at IPITA congress – Oxford

May 04 2017

20-23 June 2017: Defymed’s team will be present at the 16th international congress IPITA that will be held in Oxford – UK. Defymed will give a talk on the latest results of the bioartificial pancreas MailPan ® at the “Islet encapsulation & bioengineered scaffolds” session that will take place on June 22, from 11:45 to 12:45. This worldwide leading congr...

Defymed at the 1rst MEDFIT Business Convention – Grenoble

May 04 2017

28-29 June 2017: Defymed will particpate at the 1rst MEDFIT convention that will be held in Grenoble- France. MedFIT is the first European business convention dedicated to innovation partnerships in the field of medical technologies, diagnostics and IVD. The event gathers all the actors in the innovation cycle from research to market in addition to key playe...

Defymed enters partnership with Semma Therapeutics

December 12 2016

Strasbourg, December 12, 2016: Defymed announces a strategic collaboration with Semma Therapeutics, an American biotechnology company specialising in the development of cell therapies for the treatment of diabetes, with the goal of developing of an innovative solution for treating type-1 diabetes. The collaboration is aimed at pre-clinical validation of the...

Defymed winner of the Medstartup-Galien Awards 2016

October 28 2016

October 27, 2016 – New York: Defymed is the winner at the Medstartup- Galien Awards 2016 – Ca...

Defymed and Symbiose biomaterials funded for the CODEPI project

October 27 2016

October 26, 2016: Defymed and Symbiose Biomaterials SA, a Belgian startup company specialised in the development of products based on molecular biomimetics, mounted the CODEPI project. This project, cofunded by the Alsace and Wallonian regions, with the help of the health clusters Alsace Biovalley and BIOWIN, aims to develop a compress impregnated with a for...

Defymed nominated for the Medstartup awards 2016 in New York

September 06 2016

September 6, 2016: Defymed is nominated for the Medstartup awards 2016, an initiative of the Galien Foundation & Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. In the frame of this contest, Defymed collaborates with Semma Therapeutics to obtain a preclinical v...

Defymed Receives Support from JDRF to Fight Type 1 Diabetes

July 12 2016

Strasbourg, July 12, 2016 : Defymed today announced a partnership with JDRF, the leading global organization funding type 1 diabetes (T1D) research. This new investment gives Defymed the opportunity to advance its pre-clinical studies in order to demonstrate the MailPan ® immunoprotection properties, safety and function. This is an essential step before begi...

Defymed at BIOPHARM AMERICA– Boston

July 11 2016

13-15 Septembre 2016: Defymed will be present at the BIOPHARM AMERICA exhibition 2016 in Boston- USA. That event will be a great opportunity to discuss our latest news and to Partner together. We are looking forward to meeting you! Contact us For more info on Biopharm

Defymed at RESI conference – Boston

July 11 2016

13 Septembre 2016: Defymed’s CEO, Dr Séverine SIGRIST will be present at the RESI ( Redefining Early Stage Investments) conference 2016 in Boston- USA. It will be a great opportunity to meet you and discuss Defymed’s innovations and business. For any enquiry : Contact us For more info on RESI

Defymed rewarded at the 44th International exhibition of Inventions Geneva

April 19 2016

Richard Bouaoun and Charles-Thibault Burcez at the 44th International Exhibition of inventions Genev...

Defymed will be exhibiting at the 44th International Exhibition of Inventions Geneva

January 20 2016

13-17 April 2016: Defymed will be exhibiting at the 44th International Exhibition of Inventions Geneva – Switzerland. With more than 750 participants – from a record of 48 countries – and around 1’000 inventions, the International Exhibition of Inventions of Geneva has confirmed its position as the world’s most important specialized meeting place. Many exhib...